MorphoSys AG
MorphoSys AG (MOR) Revenue
Annual & quarterly revenue history · segment & region breakdown
MOR · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsMorphoSys AG trailing twelve-month (TTM) revenue is $0.20B, a decrease of 14.37% year-over-year from $0.24B in FY2023.
Revenue trend
2023 – 2004 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2023-12-31 | $0.24B | -$0.04B | -14.37% |
| 2022-12-31 | $0.28B | +$0.10B | +54.94% |
| 2021-12-31 | $0.18B | -$0.15B | -45.19% |
| 2020-12-31 | $0.33B | +$0.26B | +356.69% |
| 2019-12-31 | $0.07B | -$0.00B | -6.13% |
| 2018-12-31 | $0.08B | +$0.01B | +14.45% |
| 2017-12-31 | $0.07B | +$0.02B | +34.27% |
| 2016-12-31 | $0.05B | -$0.06B | -53.17% |
| 2015-12-31 | $0.11B | +$0.04B | +66.03% |
| 2014-12-31 | $0.06B | -$0.01B | -17.93% |
Compare revenue vs peers
BiotechnologyCompare MOR revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income MorphoSys AG receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
MorphoSys AG reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in EUR.
Data sourced from MorphoSys AG's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
MOR revenue · 4 questionsMOR's trailing twelve-month (TTM) revenue is $0.20B. That is a decrease of 14.37% year-over-year from $0.24B in FY2023.
▸ Source: FMP · MorphoSys AG SEC filings · GAAP · MorphoSys AG SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026